NCT06293820View on ClinicalTrials.gov

A Study Of TL-925 For The Treatment of AC

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 11, 2024

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Allergic Conjunctivitis
Interventions
DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (1)

01810

Andover Eye Associates, Andover

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY

NCT06293820 - A Study Of TL-925 For The Treatment of AC | Biotech Hunter | Biotech Hunter